Marcin Frąckiewicz

Spruce Biosciences’ meteoric rise began with a game-changing regulatory win. On October 6, the company announced that the FDA had granted Breakthrough Therapy Designation to its lead drug, tralesinidase alfats2.tech. TA-ERT is an experimental enzyme replacement therapy targeting Sanfilippo Syndrome Type B – a rare, inherited lysosomal storage disease that causes severe neurological decline in childrenstocktwits.com. The FDA’s BTD endorsement signals that early data for TA-ERT show “substantial improvement” over existing options for this deadly disease, and it unlocks special support to speed the drug’s development. In practical terms, a Breakthrough designation means Spruce will receive expedited FDA guidance and priority review for TA-ERT, potentially shaving years off the approval timelinets2.techstocktwits.com. Spruce’s CEO Javier Szwarcberg hailed the designation as “validation of TA-ERT’s potentially transformative clinical impact,” and confirmed the company is on track to submit a full approval application in the first quarter of 2026azat.tvstocktwits.com. If regulators agree, TA-ERT could become the first-ever approved therapy for Sanfilippo Syndrome Type B, offering hope to affected families. News of the FDA breakthrough instantly galvanized investors. SPRB had been a tiny micro-cap stock – essentially off the market’s radar – prior to October. The BTD announcement flipped that script overnight. When trading opened